Clinical TrialAug 12, 2026, 06:08 AM
Clinuvel Advances Injectable Peptide Platform VLRX-L After Pre-clinical Data
AI Summary
Clinuvel Pharmaceuticals provided an update on its VLRX-L controlled-release liquid injectable peptide formulation platform. Following promising pre-clinical data, the company is refining a candidate formulation that demonstrated a superior release profile over the targeted peptide delivery window. Further pre-clinical studies are planned for Q1 2027, with manufacturing scale-up being scoped for the platform, which initially focuses on melanocortin peptides.
Key Highlights
- Clinuvel is advancing its VLRX-L controlled-release injectable liquid peptide platform.
- First candidates selected for further preclinical studies are scheduled for Q1 2027.
- One candidate formulation demonstrated a superior release profile in pre-clinical models.
- Optimisation of the candidate formulation is ongoing at the VALLAURIX RD&I Centre.
- Initial focus for the VLRX-L platform is on melanocortin peptides.
- Manufacturing scale-up for the platform is currently being scoped.
Price Impact
More from CUVL